



Strengthening of Pherecydes Pharma's patent portfolio with two new patents granted in the United States

Nantes, France, February 16, 2021 – 6 pm CET– Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, today announced that the United States Patent and Trademark Office (USPTO) has granted two patents for its *anti-Pseudomonas Aeruginosa* and *anti-E. Coli* phages, in the United States.

Guy-Charles Fanneau de La Horie, CEO of Pherecydes Pharma, says: *"We are very pleased that the USPTO has granted us these two new patents for our anti-Pseudomonas aeruginosa and anti-E. Coli phages. These two new patents in the world's leading healthcare market greatly expand the geographical areas in which our phages are now protected. This is a further evidence of the relevance of the intellectual property strategy we have implemented. We will continue to protect our champion phages with this now proven strategy."*

Pherecydes Pharma has an active portfolio of four patents, each covering multiple phages and their variants against the target bacteria: *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Escherichia Coli*. While some of these patents are currently pending, others have already been granted in major jurisdictions such as the United States, Europe, Japan, Australia, Hong Kong and Israel.

About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two thirds of hospital-acquired resistant infections: *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*. The concept of precision phage therapy has been successfully applied in 22 patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research.

For more information, www.pherecydes-pharma.com

Contacts

Pherecydes Pharma

Philippe Rousseau
CFO
investors@pherecydes-pharma.com

NewCap

Dusan Oresansky
Investor Relations
pherecydes@newcap.eu
T.: +33 1 44 71 94 92

NewCap

Nicolas Merigeau
Media Relations
pherecydes@newcap.eu
T.: +33 1 44 71 94 98



Disclaimer

This document does not constitute or should not be considered as a public offering, an offer to subscribe company's securities or a public solicitation in preparation for a public offering of Pherecydes Pharma's securities. Pursuant to the provisions of Article L.411-2 of the French Monetary and Financial Code and Article 211-2 of the General Regulations of the French Market Authority (Autorité des Marchés Financiers - AMF), any offer for a total amount of less than €8,000,000 shall not give rise to a Prospectus approved by the AMF. This press release does not constitute a prospectus within the meaning of Regulation (EU) No 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation").

In the United Kingdom, this document is addressed to and intended solely for those persons who are « qualified investors » pursuant to Article 2(1)(e) (i), (ii) and (iii) of the Prospectus Directive of the European Union, and who are also considered as (i) « investment professionals » (persons with professional investing experience) pursuant to Article 19(5) of the 2000 Financial Services and Markets Act (Financial Promotion) Order 2005 (as amended, the « Order), (ii) persons included in the scope of Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) persons invited or urged to participate in an investment activity (pursuant to Article 21 of the 2000 Financial Services and Markets Act) in connection with the issuance or the sale of financial securities (all such persons being designated together as the "Interested Persons"). In the United Kingdom, this document is addressed solely to the Interested Persons and no person other than an interested person must use or rely on this document. Any investment or investment activity to which this document refers shall be accessible only to the Interested Persons and shall be undertaken only with Interested Persons.

This document does not constitute an offer to sell Pherecydes Pharma's securities in the United States of America. Pherecydes Pharma's securities cannot be sold in the United States of America without the registration or an exemption from registration under the United States Securities Act of 1933, as amended. Pherecydes Pharma is not contemplating registering an offer or any public offering of securities, in the United States of America.

The diffusion of this document in other countries may result in violating applicable rules governing securities law. This document does not constitute an offer of Pherecydes Pharma's securities in the United States of America, Canada, Australia, Japan or in any other country. This document must not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

Finally, this press release may be drafted in French and English languages. If both versions are interpreted differently, the French language version shall prevail.